Related Experiment Video
Updated: Aug 4, 2026
09:03
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
8.8K
Meeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment
Mark Alasandro1, Dilip Choudhury2, Kim Huynh-Ba3
1Adamis Pharmaceuticals, San Diego, CA USA.
AAPS Open
|December 6, 2021
Summary
This workshop reviewed vaccine stability challenges for rapid development and deployment. Key topics included analytical characterization, stability modeling for Emergency Use Authorization (EUA), and distribution strategies.
Area of Science:
- Pharmaceutical Sciences
- Vaccinology
- Regulatory Science
Background:
- The American Association of Pharmaceutical Scientists (AAPS) Stability Community convened a virtual workshop on vaccine stability.
- The workshop focused on accelerating vaccine development and deployment during the pandemic.
Purpose of the Study:
- To review key topics discussed at the AAPS workshop on vaccine stability.
- To highlight challenges and strategies for rapid vaccine development, characterization, and deployment.
Main Methods:
- Review of presentations and panel discussions from the AAPS virtual workshop.
- Synthesis of information on vaccine stability considerations, analytical characterization, and modeling.
Main Results:
- Discussion of challenges in accelerating vaccine development and analytical techniques for shelf-life determination.
- Exploration of vaccine stability modeling for Emergency Use Authorization (EUA) approaches.
- Emphasis on the role of stability studies in vaccine distribution and pandemic response.
Conclusions:
- Techniques discussed are broadly applicable to various vaccine types, including mRNA vaccines.
- Expert insights were shared on EUA approval and deployment challenges for novel vaccine technologies.
Related Concept Videos
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:16Drug Product Stability
The long-term stability of drug products is critical to ensuring their quality, safety, and effectiveness over time. Stability directly influences a product's ability to maintain its intended characteristics, ensuring it performs as expected during its intended shelf life. Key attributes such as drug potency, impurities, dissolution, and other physicochemical measures of performance are tested to assess stability. These parameters indicate how well the product retains its quality over time and...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:21Vaccines
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...